Actualización en el tratamiento de la infección bronquial

  1. F. Casas Maldonado 1
  2. C. Oliveira Fuster 2
  3. A. Dorado Galindo 2
  4. M. Montes Ruiz-Cabello
  1. 1 Servicio de Neumología, Hospital Universitario San Cecilio de Granada
  2. 2 Servicio de Neumología, Hospital Universitario Carlos Haya de Málaga
Revista:
Revista española de patología torácica

Año de publicación: 2008

Volumen: 20

Número: 4

Páginas: 49-59

Tipo: Artículo

Referencias bibliográficas

  • Vendrell M, De Gracia J, Olveira C, Martínez MA, Girón R, Máiz L, Cantón R, Coll R, Escribano A, Solé A. Normativa SEPAR: diagnóstico y tratamiento de las bronquiectasias. Arch Bronconeumol 2008. En prensa. Disponible en: www.separ.es/publicaciones/normativas_y_procedimientos.html
  • Pasteur AC, Helliwell SM, Houghton SJ, Web SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000; 162:1277-1284.
  • Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005; 12:205- 209.
  • Goss CH, Burns JL. Exacerbations in cystic fibrosis • 1: Epidemiology and pathogenesis. Thorax 2007; 62:360-367.
  • Bell SC, Robinson PJ. Exacerbations in cystic fibrosis • 2: Prevention. Thorax 2007; 62:723-732.
  • Smyth AR, Elborn JS. Exacerbations in cystic fibrosis • 3: Treatment. Thorax 2008; 63:180-184.
  • Chang AB, Bilton D. Exacerbations • 4: Non-CF bronchiectasis. Thorax 2008;63:269-276.
  • Vendrell Relat M. Definición, fisiopatología y etiología de las bronquiectasias. En: Martínez García MA (Dir). Bronquiectasias no debidas a Fibrosis Quística. Monografías en Neumología. Neumología y Salud SL. Zaragoza 2008; 15-28.
  • Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular Mechanisms. Eur Respir J 2008; 31:396-406.
  • Angrill J, Agusti C, De Celis R, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med. 2001; 164:1628-1632.
  • Cantón Moreno R, Gómez de la Pedrosa E., Fernández-Olmos A. En: Martínez García MA (Dir). El problema de la Pseudomonas aeruginosa. Bronquiectasias no debidas a Fibrosis Quística. Monografías en Neumología. Neumología y Salud SL. Zaragoza 2008; 73-93.
  • Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med. 2007; 101:1163-1170.
  • Máiz Carro L. Bronquiectasias: manejo de las agudizaciones. En: Martínez García MA (Dir). Bronquiectasias no debidas a Fibrosis Quística. Monografías en Neumología. Neumología y Salud SL. Zaragoza 2008; 15-28.
  • Martínez-García MA. Bronquiectasias ¿Todavía una enfermedad huérfana?. Arch Bronconeumol. 2005; 41:407-409.
  • De Gracia J, Vendrell M, Álvarez A, Pallisa E, Rodrigo MJ, De la Rosa D, et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol. 2004; 4:745-753.
  • Vendrell M, De Gracia J, Rodrigo MJ, Cruz MJ, Álvarez A, García M, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology. Chest. 2005; 127:197-204.
  • De Gracia Roldán, Álvarez Fernández A. En: Martínez García MA (Dir). Bronquiectasias no debidas a Fibrosis Quística. Monografías en Neumología. Neumología y Salud SL. Zaragoza 2008; 95-112.
  • Evans DJ, Greenstone M. Long term antibiotics in the management of non-CF bronchiectasis-do they improve outcome?. Respir Med. 2003; 97:851-858.
  • Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev. 2007; 2:CD001392.
  • Ten Hacken NHT, Wijkstra PJ, Kerstjens HAM. Treatment of bronchiectasis in adults. BMJ 2007; 335:1089-1093.
  • Martínez-García MA, Perpiñá M, Román P, et al. Determinants of quality of life in patients with clinically stable bronchiectasis. Chest 2005; 128:739-745.
  • Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000; 162:481-485.
  • Flume PA, O’Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007; 176:957-969.
  • Couch LA. Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest 2001; 120:114S-117S
  • Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005; 127:1420-1426.
  • Drobnic ME, Suñe P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis bronchiectasis and chronic bronchial infection with Pseudomona aeruginosa. Ann Pharmacother. 2005; 39:39-44.
  • Steinfort DP, Steinfort C. Effect of long-term nebulized colistin and lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J 2007; 37:495-498.
  • Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005; 60:239-243.
  • Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, et al. Inhaled steroids improve quality of life in patients with steadystate bronchiectasis. Resp Med. 2006; 100:1623-1632.
  • Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003; 290:1749-1756.
  • Davis G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax. 2004; 59:540-541.
  • Mutalithas K, Watkin G, Willig B, et al. Improvement in health status following bronchopulmonary hygiene physical therapy in patients with bronchiectasis. Respir Med. 2008; 102:1140-1144.
  • Havasi V, Hurst CO, Briles TC, et al. Inhibitory effects of hypertonic saline on P. aeruginosa motility.Journal of Cystic Fibrosis 2008; 7:267-269.
  • Olveira C, Olveira G*, Dorado A, et al. Gasto energético en sujetos adultos con Fibrosis Quística (FQ): concordancia entre la calorimetría indirecta y diferentes fórmulas estimativas Arch Bronconeumol 2007; 43:366-372.
  • Olveira G, Padilla A, Olveira C. Soporte nutricional en el paciente con patología pulmonar, enfermedad pulmonar obstructiva crónica y fibrosis quística. En: Bellido D, De Luis D (eds) Manual de Metabolismo y Nutrición. Madrid: Díaz de Santos SA, 2006; 455-470. ISBN:84-7978-766-X.
  • Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005; 26:1138-80.
  • Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001; 139:359-365.
  • lowite J, Spiegler P, Chawla S. Bronchiectasis: new findings in the pathogenesis and treatment of this disease. Current Opinion in Infectious Diseases 2008, 21:163-167.
  • Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 2008; 21:71-76.
  • Fernandes B, Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD006682. DOI: 10.1002/14651858.CD006682.pub2.
  • Bilton D, Henil N, Morrissey B., et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of P. aeruginosa infection in adult bronchiectasis. Chest 2006; 130:1503- 1510.